Merck & Co., Inc: Renal Insufficiency trials

The registry lists 32 Renal Insufficiency studies with Merck & Co., Inc as lead sponsor. 2 are open to participants now and 17 have results posted.

Phase 1 25Phase 2 2Phase 3 3Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013)Not yet recruitingNCT07922174Phase 1
• A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)RecruitingNCT07734610Phase 1
• A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)CompletedNCT06643377Phase 1Results posted
• A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)CompletedNCT06295796Phase 1Results posted
• A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)CompletedNCT05386758Phase 1Results posted
• A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)CompletedNCT04994522Phase 1Results posted
• Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)TerminatedNCT04678505Phase 1Results posted
• Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)CompletedNCT03311841Phase 1Results posted
• Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)CompletedNCT03259087Phase 1Results posted
• The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)CompletedNCT03108924Phase 1Results posted
• A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)CompletedNCT02641067Phase 1Results posted
• Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001)CompletedNCT02341599Phase 1Results posted
• Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)CompletedNCT02011490Phase 1Results posted
• Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)CompletedNCT01948986Phase 1Results posted
• The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)CompletedNCT01937975Phase 1Results posted
• A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)TerminatedNCT01558674Phase 1Results posted
• Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)CompletedNCT01512667Phase 1Results posted
• Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)CompletedNCT01432535Phase 1Results posted
• Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal ImpairmentTerminatedNCT01104662Phase 4Results posted
• A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)CompletedNCT07348237Phase 1
• A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)CompletedNCT06814119Phase 1
• Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal ImpairmentTerminatedNCT02508740Phase 1
• The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)WithdrawnNCT01832103Phase 1
• A Pharmacokinetics and Safety Study in Subjects With Renal ImpairmentCompletedNCT01452828Phase 1
• Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)CompletedNCT01122667Phase 1
• Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure PatientsCompletedNCT00652782Phase 2
• Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV TherapyCompletedNCT00443690Phase 3
• A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)CompletedNCT00418366Phase 1
• PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal FunctionCompletedNCT00354458Phase 3
• PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal FunctionCompletedNCT00328692Phase 3
• Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal ImpairmentCompletedNCT00159614Phase 2
• Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure InfectionsTerminatedNCT00102947Phase 4